Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 7:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 172 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Warfarin Clear all
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT02452918
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infection
Interventions
Oritavancin, Warfarin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Somers Point, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 7, 2026, 7:59 PM EDT
Not listed Phase 3 Interventional

Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)

NCT03147638
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
Warfarin, NOAC
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 97 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 7, 2026, 7:59 PM EDT
Completed No phase listed Observational Results available

Anticoagulant Utilization Pattern

NCT01847560
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
333,664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 7, 2026, 7:59 PM EDT
Completed No phase listed Observational

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666
View directory record Official record
Conditions
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Interventions
Oral Anticoagulant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
39,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Oakland, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of Danicopan

NCT04709094
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Warfarin, Bupropion, Ethinyl Estradiol/Norethindrone
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

NCT01133366
View directory record Official record
Conditions
Healthy
Interventions
warfarin sodium, mipomersen sodium; warfarin sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 7, 2026, 7:59 PM EDT
Completed No phase listed Observational

Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin

NCT00878137
View directory record Official record
Conditions
Antiphospholipid Syndrome
Interventions
INR by point-of-care instruments and venopuncture
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 7, 2026, 7:59 PM EDT
Not listed Not applicable Interventional

Warfarin Patient Self-management Implementation in the US Healthcare System

NCT04766216
View directory record Official record
Conditions
Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases
Interventions
Patient self-management, Usual care provided by anticoagulation providers
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Loma Linda, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 7, 2026, 7:59 PM EDT
Suspended Not applicable Interventional

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148
View directory record Official record
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 7, 2026, 7:59 PM EDT
Completed No phase listed Observational Results available

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

NCT02061748
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Observational
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 89 Years
Enrollment
38,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

NCT00404274
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) oral tablets, Warfarin oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Gainesville, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Not applicable Interventional

Use of Phytonadione to Reduce International Normalized Ratio (INR) Variability in Patients on Long-term Warfarin Therapy

NCT01474460
View directory record Official record
Conditions
Coagulation Delay
Interventions
phytonadione
Dietary Supplement
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

NCT01747746
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
Interventions
Rivaroxaban, Warfarin and Enoxaparin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With a Potential Alzheimer's Disease Compound

NCT00726726
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2008 · Synced Oct 7, 2026, 7:59 PM EDT
Active, not recruiting No phase listed Observational

Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative

NCT03910933
View directory record Official record
Conditions
Health Literacy, Anticoagulation
Interventions
elearning patient information
Other
Lead sponsor
University of Alberta
Other
Eligibility
Up to 18 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Results available

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial

NCT00041938
View directory record Official record
Conditions
Heart Disease, Stroke, Ischemic Heart Disease, Myocardial Infarction
Interventions
aspirin, Warfarin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2,305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
54
States / cities
Tucson, Arizona • Santa Clara, California • West Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

NCT01662908
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis
Interventions
edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Dothan, Alabama • Montgomery, Alabama • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Results available

Secondary Prevention of Venous Thrombo Embolism (VTE).

NCT00329238
View directory record Official record
Conditions
Thromboembolism
Interventions
Dabigatran, Warfarin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Not applicable Interventional

Genotype-Guided Warfarin Therapy Trial

NCT00904293
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Artificial Heart Valve
Interventions
Genotype-guided dose determination, Non-genotype guided warfarin dosing
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT

NCT01006733
View directory record Official record
Conditions
Thromboembolism
Interventions
Pharmacogenetic, Target INR 1.8
Genetic · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
1,598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

NCT00914667
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
warfarin, Warfarin plus Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers

NCT01178853
View directory record Official record
Conditions
Healthy
Interventions
Warfarin, Warfarin 5mg + Rosuvastatin 40 mg once daily (QD), Warfarin 5 mg + Pitavastatin 4mg once daily (QD)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 7, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of 2012 Bioequivalence Standards for Warfarin

NCT02574754
View directory record Official record
Conditions
Healthy
Interventions
warfarin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 7, 2026, 7:59 PM EDT
Completed No phase listed Observational

Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling

NCT01964794
View directory record Official record
Conditions
Stable Target INR
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
60 Years to 69 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 7, 2026, 7:59 PM EDT